US Stock MarketDetailed Quotes
QNCX Quince Therapeutics
- 1.540
- -0.080-4.94%
Close Nov 1 16:00 ET
- 1.530
- -0.010-0.65%
Post 18:54 ET
66.65MMarket Cap-1222P/E (TTM)
1.720High1.420Low604.27KVolume1.630Open1.620Pre Close936.59KTurnover1.75%Turnover RatioLossP/E (Static)43.28MShares1.79052wk High1.42P/B53.29MFloat Cap0.51252wk Low--Dividend TTM34.60MShs Float121.980Historical High--Div YieldTTM18.52%Amplitude0.512Historical Low1.549Avg Price1Lot Size
About Quince Therapeutics Company
Quince Therapeutics, Inc.(formerly Cortexyme, Inc.） is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Company Profile
SymbolQNCX
Company NameQuince Therapeutics
Listing DateMay 9, 2019
Founded2012
CEOMr. Dirk Thye, M.D.
MarketNASDAQ
Employees32
Fiscal Year Ends12-31
Address611 Gateway Boulevard,Suite 273
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-910-5717
Websitehttp://quincetx.com
Company Executives
-
Name
- Position
- Salary
-
Dirk Thye, M.D.
- Chief Executive Officer, Chief Medical Officer and Director
- 1.33M
-
Brendan Hannah
- Chief Operating Officer, Chief Compliance Officer, Chief Business Officer, Principal Financial Officer and Principal Accounting Officer
- 847.50K
-
Dr. Charles S. Ryan, J.D.,PhD
- President
- 817.56K
-
David A. Lamond
- Chairman of the Board
- 106.06K
-
Rajiv Patni, M.D.
- Director
- --
-
Dr. Luca Benatti, PhD
- Independent Director
- 52.80K
-
Christopher J. Senner
- Independent Director
- 87.56K
-
Dr. Margaret A. McLoughlin, PhD
- Independent Director
- 82.06K
-
June Bray
- Independent Director
- 80.06K
-
Dr. Una S. Ryan,PhD
- Lead Independent Director
- 98.56K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
